Retrospectoscopy is an exact science ( unlike flexible cystoscopy which although being a “gold standard” also has false positive and negative results 😊!). IMHO ,and I alluded to this some time ago and I think some here agree, PEB has come off badly by taking on the AUA and a medical system which has huge flaws and is dominated by an insurance industry mentality. The phrase “medically necessary” is a crucial issue here and the interpretation leaves out personal considerations of the patients and seems to override primary care considerations. CxBladder in its various forms is a very good test and it would be very unfortunate if it falls through the cracks ( admittedly very large ones) of the US system. I have long thought a UK/Europe approach would have encountered far less resistance and had a far greater uptake. I also suspect CxBladder may have been significantly overpriced? Sadly this 20 year saga may end in the “How not to” section of business education textbooks or their equivalents.
It's been an interesting twenty years all right. I sold my last remaining shares after the trading halt came off last year when they announced Novitas potentially withdrawing coverage. Despite the optimism from the company that it was an unlikely event, I couldn't reconcile this with the fact that Novitas would not advise such a move if they weren't serious. I had hoped to look at buying back in if the outcome was positive but that's not on the cards.
Over the years I have attended a few of the company annual meetings in Dunedin and talked with some of the PEB staff. They are a very talented group of people, and it is them I feel most sorry for in this situation as many may well lose their jobs. It would be a sad loss.
Originally Posted by Balance
Reply With Quote
Bookmarks